Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”

View Full Paper
Ask AI
Bookmark
Share

Authors

TSTina M. SchnoederFPFrancesca PalandriFBFilippo Branzanti

Discussion

Loading...

Member takes

Overview

Observational analysis reveals differential molecular responses in MPN double driver patients, suggesting varied clinical management approaches.

Key Points

  • Patients with double driver mutations show distinct survival outcomes, particularly influenced by JAK2 and CALR mutations.
  • Survival for JAK2/MPL co-mutated cases is significantly worse, averaging 3.8 years compared to better outcomes for JAK2/CALR.
  • Analysis of a cohort from the German MPN Study Group Registry confirmed the prevalence of double driver mutations in clinical settings.
  • Genetic evaluations of hematopoietic cells indicate that treatment responses, especially to interferon, vary based on mutation profiles.

Cite This Study

Schnoeder et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d41chttps://doi.org/10.1182/blood-2025-1021
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical features and outcomes of myeloproliferative neoplasm patients with MPL mutations and concurrent JAK2/calr mutations2025
  2. 2Clinical features and outcomes of myelofibrosis patients with MPL mutations2025
  3. 3Myeloproliferative neoplasm driver mutations (JAK2/CALR/MPL) in chronic myelomonocytic leukemia are associated with an increased risk of blast transformation2025
  4. 4NGS and emerging molecular scenarios in chronic myeloproliferative neoplasms: a case of double mutated polycythemia vera2026
  5. 5Comparison of the clinicopathological features in myeloproliferative or myelodysplastic neoplasms with <i>SF3B1</i> / <i>JAK2</i> , <i>SF3B1</i> / <i>CALR</i> , or <i>SF3B1</i> / <i>MPL</i> co-mutations2025